Vestal Point Capital LP trimmed its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 34.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 395,000 shares of the company's stock after selling 205,000 shares during the quarter. Vestal Point Capital LP owned approximately 1.33% of Dianthus Therapeutics worth $10,815,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock valued at $16,135,000 after buying an additional 384,182 shares in the last quarter. Janus Henderson Group PLC bought a new position in Dianthus Therapeutics during the 1st quarter worth about $11,251,000. Great Point Partners LLC raised its holdings in shares of Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock valued at $19,615,000 after purchasing an additional 132,929 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock valued at $4,543,000 after buying an additional 97,362 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock worth $2,095,000 after buying an additional 72,509 shares during the period. Hedge funds and other institutional investors own 47.53% of the company's stock.
Dianthus Therapeutics Stock Up 0.7 %
Shares of Dianthus Therapeutics stock traded up $0.16 on Friday, reaching $23.99. 79,806 shares of the stock were exchanged, compared to its average volume of 206,107. Dianthus Therapeutics, Inc. has a twelve month low of $6.58 and a twelve month high of $33.77. The business has a 50 day moving average price of $26.74 and a two-hundred day moving average price of $26.57. The firm has a market capitalization of $710.10 million, a price-to-earnings ratio of -9.53 and a beta of 1.84.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.07 million. Research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on DNTH. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Raymond James increased their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, November 11th. Finally, Wedbush lowered their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a research note on Friday, August 9th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $46.43.
View Our Latest Report on DNTH
About Dianthus Therapeutics
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
